{"organizations": [], "uuid": "dac81af97a56dcae4bcdf67ba5c79a5900e9ef2f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180524.html", "section_title": "Archive News &amp; Video for Thursday, 24 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/recro-pharma-fda/fda-declines-to-approve-recro-pharmas-non-opioid-pain-shot-idUSL3N1SV4I4", "country": "US", "domain_rank": 408, "title": "FDA declines to approve Recro Pharma's non-opioid pain shot", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-05-24T19:08:00.000+03:00", "replies_count": 0, "uuid": "dac81af97a56dcae4bcdf67ba5c79a5900e9ef2f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/recro-pharma-fda/fda-declines-to-approve-recro-pharmas-non-opioid-pain-shot-idUSL3N1SV4I4", "ord_in_thread": 0, "title": "FDA declines to approve Recro Pharma's non-opioid pain shot", "locations": [], "entities": {"persons": [{"name": "sharnya g", "sentiment": "none"}, {"name": "tamara mathias", "sentiment": "none"}, {"name": "shailesh kuber", "sentiment": "none"}, {"name": "recro", "sentiment": "none"}], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "negative"}, {"name": "recro pharma", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "The U.S. Food and Drug Administration on Thursday declined to approve Recro Pharma’s IV meloxicam noting the pain-relieving effect of the drug did not meet its expectations.\nThe drug is a non-opioid injection to treat moderate-to-severe pain.\nUnlike the drug’s oral version, which has been on the market for several years, Recro’s intravenous formulation is long-acting for treating acute pain, particularly in patients who have undergone surgery. (Reporting by Sharnya G and Tamara Mathias; Editing by Shailesh Kuber)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-24T19:08:00.000+03:00", "crawled": "2018-05-25T16:06:16.001+03:00", "highlightTitle": ""}